Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

United Therapeutics

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of United Therapeutics' 2013 cardiovasular sales performance.

Rare disease therapies head the ‘class of 2015’

Rare disease therapies head the ‘class of 2015’

have a treatment option in the form of Wellstat Therapeutics' Xuriden (uridine triacetate). ... USA. dinutuximab. Unituxin. neuroblastoma. anti-GD2 antibody. United Therapeutics. USA. elotuzumab. Empliciti.

FDA approvals hit 19-year high

FDA approvals hit 19-year high Orkambi (ivacaftor plus lumacaftor) and United Therapeutics' paediatric bran cancer therapy Unituxin (dinutuximab).

Actelion claims first approval for PAH therapy Uptravi

Actelion claims first approval for PAH therapy Uptravi Uptravi will compete in the US marketplace with another oral prostacyclin agonist - United Therapeutics' Orenitram (treprostinil) - and Actelion is banking that the data behind its new drug will allow it to

GSK earns expanded approval for Volibris in Europe

GSK earns expanded approval for Volibris in Europe s Adempas (riociguat) and United Therapeutics' Orenitram (trepostinil).

Gilead receives FDA approval for PAH combo

Gilead receives FDA approval for PAH combo Additionally there will be competition from Bayer's Adempas (riociguat), which was cleared by the FDA in 2013, and United Therapeutics' Remodulin (treprostinil).

1 2 3 4 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
KVA Digital

KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...

Latest intelligence

Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....
Could formulary intelligence be your brand differentiator?
Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
Lara Meyer
How COVID-19 is accelerating the threat of antimicrobial resistance
Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...

Infographics